港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

瑞博生物-B

55.050

+0.1500.27%

成交量：5.98萬

成交額：330.82萬

市值：93.89億

市盈率：-23.14

高：56.850

開：54.900

低：53.850

收：54.900

52周最高：95.800

52周最低：51.200

股本：1.71億

香港流通股本：1.71億

量比：0.34

換手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-2.379

淨資產收益率：--

總資產收益率：--

市淨率：-141.88

市盈率(LYR):-23.14

市銷率: 46.02

資料載入中...

總覽公司新聞資訊公告

瑞博生物-B(06938.HK)：建議撤銷監事會

瑞博生物-B(06938)擬採納H股購股權計劃及H股激勵計劃

瑞博生物-B(06938)：Anders Gabrielsen獲委任為公司首席醫學官

瑞博生物-B(06938)2025年實現收入約1.485億元，按年增加4.1%

瑞博生物－Ｂ(06938)出現大手賣出9.86萬股，成交價$53.45，涉資527.017萬

阿斯达克财经

瑞博生物-B(06938.HK)擬3月25日舉行董事會會議以審批年度業績

醫藥行業月報2026/02：創新藥BD超預期，全球化合作推動價值重構

瑞博生物-B（06938）更新2026年2月股份變動月報表，股本增至170,554,910股

《大行》花旗首予瑞博生物(06938.HK)「買入」評級目標價102元

阿斯达克财经

瑞博生物-B03月03日主力淨流出70.8萬元散户資金買入

GSK乙肝新藥叩門上市，小核酸商業化拐點已至

瑞博生物-B啓動RBD7022注射液治療高脂血症III期臨床試驗

瑞博生物-B(06938)：RBD7022注射液即將於中國啓動用於治療高血脂症適應症的 III期臨床試驗

LDL-C降低75%！齊魯製藥/瑞博生物降脂siRNA療法啓動III期臨床

医药魔方Info

瑞博生物-B02月27日主力淨流入2386萬元散户資金拋售

中郵證券：siRNA藥物機制優勢突出遞送為核心技術

智通财经网

國泰海通：FXI引領抗凝藥產業新變革多技術路線競逐藍海

【國聯民生醫藥】醫藥周報20260223：春節期間醫藥行業重點事件梳理

医耀科技创新骑手

45天狂攬490億美元，2026中國創新藥BD加速升温

中金：首予瑞博生物-B(06938)「跑贏行業」評級目標價100港元

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06938/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":55.05,"timestamp":1774426110799,"preClose":54.9,"halted":0,"volume":59800,"delay":0,"changeRate":0.002732240437158444,"floatShares":170554910,"shares":170554910,"eps":-2.378693908193979,"marketStatus":"未開盤","change":0.15,"latestTime":"03-25 16:08:30","open":54.9,"high":56.85,"low":53.85,"amount":3308150,"amplitude":0.054645,"askPrice":55.7,"askSize":400,"bidPrice":55,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.6071483218800573,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":54.9,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0.335804,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-2.378694,"volumeRatio":0.335804,"shares":170554910,"dividePrice":0,"high":56.85,"amplitude":0.054645,"preClose":54.9,"low":53.85,"week52Low":51.2,"pbRate":"-141.88","psRate":"46.02","week52High":95.8,"institutionHeld":0,"latestPrice":55.05,"committee":0.666667,"eps":-2.378693908193979,"divideRate":0,"volume":59800,"delay":0,"ttmEps":-1.6071483218800573,"open":54.9,"prevYearClose":57.97,"prevWeekClose":57.05,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":60,"twentyDayClose":71.5,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774402200000,"name":null,"time":"","dateTimestamp":1774368000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1773417600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-24","current":-34.255693,"percent":0.96,"low":-50.513246,"twenty":-48.535001,"median":-40.617956,"eighty":-38.832211,"high":-35.975036,"avg":-42.645244,"sd":4.489462,"marketCap":9363464559},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-24","current":-37.354591,"twenty":-48.535001,"median":-40.617956,"eighty":-38.832211,"marketCap":9363464559}],"updateTime":1774457778933},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622687070","title":"瑞博生物-B(06938.HK)：建議撤銷監事會","url":"https://stock-news.laohu8.com/highlight/detail?id=2622687070","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622687070?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 23:17","pubTimestamp":1774451824,"startTime":"0","endTime":"0","summary":"格隆汇3月25日丨瑞博生物-B(06938.HK)宣布，为(i)使公司公司章程符合有关举行混合式股东大会、提供电子投票及对香港联合交易所有限公司证券上市规则作出相关修订的最新监管规定；及(ii)根据《中华人民共和国公司法》、中国证券监督管理委员会发布的《上市公司章程指引》及《上市公司股东会规则》以及其他法律法规的最新监管规定(其中规定中国上市公司撤销监事会并进一步完善企业管治)，结合公司实际情况，董事会审议及批准(其中包括)有关修订公司章程、公司股东大会议事规则及董事会议事规则。同时，根据前述法律法规和监管规定，公司拟撤销公司监事会，监事会的相关职权将由董事会审计委员会行使。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260325/32098708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2622511077","title":"瑞博生物-B(06938)擬採納H股購股權計劃及H股激勵計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2622511077","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622511077?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:50","pubTimestamp":1774450252,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年3月25日，董事会议决建议采纳本公司H股购股权计划(H股购股权计划)及H股激励计划(H股激励计划，统称为“股份计划”)，惟须待本公司股东批准后，方可作实。股份计划旨在为合资格人士(包括雇员参与者、服务提供者及相关实体参与者)提供获得本公司专有权益的机会，藉以鼓励合资格人士为本公司及股东的整体利益积极工作，提升本公司及本公司股份的价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2622072754","title":"瑞博生物-B(06938)：Anders Gabrielsen獲委任為公司首席醫學官","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072754","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072754?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:38","pubTimestamp":1774449502,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，Anders Gabrielsen博士已获委任为公司首席医学官，将负责公司的整体临床开发、医学事务及监管合规;John Taylor博士已获委任为公司首席商务官，将负责公司的整体商务发展、授权引进及对外许可合作以及战略投资;甘黎明博士不再担任首席医学官，但将继续担任公司的执行董事、联席首席执行官兼全球研发总裁，均自2026年3月25日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2622756072","title":"瑞博生物-B(06938)2025年實現收入約1.485億元，按年增加4.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622756072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622756072?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:35","pubTimestamp":1774449346,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 公布2025年业绩，收入约1.485亿元，同比增加4.1%。毛利约1.35亿元，同比增加3.3%。研发开支约2.8亿元，基本持平。公告称，收入增长主要是由于勃林格殷格翰合作及兴博润销售核苷单体相关产品所产生的收入增加所致。自成立以来，公司已分别与勃林格殷格翰及齐鲁制药订立多项许可及合作协议，总交易价值超过21亿美元。根据有关协议，公司已授予Madrigal开发、生产及商业化若干siRNA资产的独家全球许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2621725501","title":"瑞博生物－Ｂ(06938)出現大手賣出9.86萬股，成交價$53.45，涉資527.017萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2621725501","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621725501?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232700,"startTime":"0","endTime":"0","summary":"[大手成交]瑞博生物－Ｂ(06938)在上午10:25出现大手卖出，成交量为9.86万，成交价为港币$53.45，涉资527.017万。至目前为止，股价跌4.382%，今日最高价为$56.0，而最低价为$53.25，总成交量为15.12万股，总成交金额港币$810.986万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603235628/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603235628/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2618138477","title":"瑞博生物-B(06938.HK)擬3月25日舉行董事會會議以審批年度業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138477","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618138477?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 18:07","pubTimestamp":1773310024,"startTime":"0","endTime":"0","summary":"格隆汇3月12日丨瑞博生物-B(06938.HK)公告，董事会会议将于2026年3月25日(星期三)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度业绩及其发布，并考虑建议派发末期股息(如有)及处理其他事务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260312/32063755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2618699505","title":"醫藥行業月報2026/02：創新藥BD超預期，全球化合作推動價值重構","url":"https://stock-news.laohu8.com/highlight/detail?id=2618699505","media":"中国银河","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618699505?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 12:07","pubTimestamp":1772942852,"startTime":"0","endTime":"0","summary":"核心观点2026开年BD超预期，重磅交易密集落地。交易金额持续提升标志着中国创新资产价值的全球合作信任体系正逐渐建立。合作新范式推动中国创新药价值重构。预计未来更多中国创新药企业达成平台级战略合作，与跨国MNC深度绑定并快速接入全球体系，实现全球利益最大化，推动估值体系重构。医药行业表现弱于沪深300。截至2026年2月28日，医药行业一年滚动市盈率为37.20倍，沪深300为14.12倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603081207369545173f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603081207369545173f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06938","06978","BK1574"],"gpt_icon":0},{"id":"1113065955","title":"瑞博生物-B（06938）更新2026年2月股份變動月報表，股本增至170,554,910股","url":"https://stock-news.laohu8.com/highlight/detail?id=1113065955","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113065955?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 17:40","pubTimestamp":1772703632,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年3月5日披露2026年2月股份变动月报。报告期为2026年2月1日至2026年2月28日。根据公告披露，已发行股份自上月底的165,813,510股增加4,741,400股至170,554,910股，法定/注册股本由人民币165,813,510元增至人民币170,554,910元。报告显示，现有2,113,987份尚未行使的期权，行使价为每股人民币3.70元，截至2028年1月9日方可开始行使。截至2026年2月28日，公司总股本数量变动后为170,554,910股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2617990575","title":"《大行》花旗首予瑞博生物(06938.HK)「買入」評級  目標價102元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617990575","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617990575?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 10:37","pubTimestamp":1772678220,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，瑞博生物-B(06938.HK) 是siRNA领域的龙头企业，拥有具差异化药物管线、领先的药物递送技术平台等核心优势。该行认为，瑞博生物的核心候选药物RBD4059，有望成为治疗血栓性疾病的突破性药物，该药销售潜力可达超过60亿美元，而该潜力被市场低估。该行首予公司“买入(高风险)”评级，目标价102元。(sl/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260127111330476_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260127111330476_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1506799/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1506799/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06938"],"gpt_icon":0},{"id":"2616043374","title":"瑞博生物-B03月03日主力淨流出70.8萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616043374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616043374?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 16:15","pubTimestamp":1772525757,"startTime":"0","endTime":"0","summary":"03月03日, 瑞博生物-B股价跌5.06%，报收61.00元，成交金额1771.5万元，换手率0.17%，振幅9.26%，量比1.30。瑞博生物-B今日主力资金净流出70.8万元，上一交易日主力净流入1308.1万元。该股近5个交易日下跌14.69%，主力资金累计净流入3623.3万元；近20日主力资金累计净流入3419.2万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303162109a445bbc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2616188413","title":"GSK乙肝新藥叩門上市，小核酸商業化拐點已至","url":"https://stock-news.laohu8.com/highlight/detail?id=2616188413","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616188413?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 19:05","pubTimestamp":1772449503,"startTime":"0","endTime":"0","summary":"截至目前，Alnylam已形成7款商业化产品梯队。英克司兰钠是全球首个siRNA降脂药，也是首款面向常见慢性病的小核酸药物，它的成功具有里程碑意义。这些技术创新，共同驱动小核酸药物治疗潜力不断释放，推动市场进入加速增长通道。2月23日，前沿生物与GSK达成独家授权协议，GSK获得两款siRNA管线全球开发、生产及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030220293595429ddf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1165985607","title":"瑞博生物-B啓動RBD7022注射液治療高脂血症III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165985607","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165985607?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410268,"startTime":"0","endTime":"0","summary":"瑞博生物-B（股票代码：06938）近日宣布，其研发的RBD7022注射液将在中国正式启动针对高脂血症治疗的III期临床试验。该试验旨在进一步评估该药物在更广泛患者群体中的安全性与有效性，标志着其在心血管代谢疾病治疗领域的研发进程迈入关键阶段。高脂血症作为常见的心血管风险因素，其创新疗法的推进备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2616877702","title":"瑞博生物-B(06938)：RBD7022注射液即將於中國啓動用於治療高血脂症適應症的 III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616877702?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:11","pubTimestamp":1772410260,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)公布，集团自主研发的RBD7022注射液已由合作方齐鲁制药有限公司(齐鲁制药)完成III期临床试验登记公示，即将启动III期临床试验。RBD7022注射液是一款靶向PCSK9的siRNA药物。PCSK9是一种酶，在调节体内胆固醇，尤其是通常被称为“LDL-C”或“坏胆固醇”的低密度脂蛋白(LDL)胆固醇的水平方面起关键作用，可作为管理高胆固醇血症的一种治疗选择，旨在降低与高胆固醇水平相关的心血管疾病风险。2023年12月，公司将RBD7022注射液在中国内地、中国香港和中国澳门开发、生产和商业化的独家权利授予齐鲁制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1161","06938"],"gpt_icon":0},{"id":"2614815508","title":"LDL-C降低75%！齊魯製藥/瑞博生物降脂siRNA療法啓動III期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2614815508","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614815508?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 14:20","pubTimestamp":1772259649,"startTime":"0","endTime":"0","summary":"2月27日，美国临床试验收录网站显示，齐鲁制药引进的小核酸新药QLC7401启动了首个III期临床试验，旨在评估该药物联合降脂药物治疗伴低密度脂蛋白胆固醇升高的原发性高胆固醇血症或混合性高脂血症的有效性和安全性。RBD7022是瑞博生物基于其自主创新的RIBO-GalSTAR肝靶向递送技术开发的GalNAc缀合siRNA药物，旨在通过靶向PCSK9治疗高血脂症。在I期研究中，接受或未接受他汀治疗的高胆固醇血症患者经RBD7022治疗后，LDL-C最大降幅均可达75%，并在6个月随访时仍然维持效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602281424059542587c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602281424059542587c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01093","BK1191","01477","06938","BK1574"],"gpt_icon":0},{"id":"2614869918","title":"瑞博生物-B02月27日主力淨流入2386萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614869918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614869918?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 16:15","pubTimestamp":1772180151,"startTime":"0","endTime":"0","summary":"02月27日, 瑞博生物-B股价涨1.93%，报收68.50元，成交金额2687.6万元，换手率0.23%，振幅2.98%，量比3.18。瑞博生物-B今日主力资金净流入2386万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.45%，主力资金累计净流入2386万元；近20日主力资金累计净流入1868.0万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161942a4cefda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2614699958","title":"中郵證券：siRNA藥物機制優勢突出 遞送為核心技術","url":"https://stock-news.laohu8.com/highlight/detail?id=2614699958","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614699958?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 11:04","pubTimestamp":1772161440,"startTime":"0","endTime":"0","summary":"中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。中邮证券主要观点如下：siRNA药物机制优势突出，递送为核心技术相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227120913a72505ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","01276","BK1161"],"gpt_icon":0},{"id":"2614772030","title":"國泰海通：FXI引領抗凝藥產業新變革 多技術路線競逐藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2614772030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614772030?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 13:37","pubTimestamp":1771997868,"startTime":"0","endTime":"0","summary":"FXI开启抗凝新时代，多技术路线竞逐蓝海研究表明，凝血因子XI是推动病理性血栓的重要因子，但在大多数情况下对正常止血并非必需，比如具有遗传性FXI缺乏的人群，血栓事件的发生率明显降低，而自发性出血的风险并未显著增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","01276","BK0276","06938","BK0028","BK1161","BK0012","LU1023057109.AUD","LU0359201612.USD","BK0188","BK0184","LU0359201885.HKD","LU2543165471.USD","BK0183","BK0201","BK1147","601211","BK1564","02611","BK1191"],"gpt_icon":0},{"id":"2613204910","title":"【國聯民生醫藥】醫藥周報20260223：春節期間醫藥行業重點事件梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2613204910","media":"医耀科技创新骑手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613204910?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 14:18","pubTimestamp":1771827529,"startTime":"0","endTime":"0","summary":"1春节期间医药行业重点事件梳理1.1创新药BD交易实现开门红，优势产品海外研发和注册进展顺利2026年春节前后，中国创新药对外BD交易实现开门红，全年交易金额有望再攀新高。根据医药魔方，截至2026年2月15日，中国创新药2026年对外BD交易首付款规模超过2025年任一季度，总金额超过2025年全年水平的1/3。3）2月17日，石药集团发布公告，SYH2082的临床试验申请获得FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223142808a71517c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223142808a71517c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161","02228","BK1515","BK1564","02268","01801","02155","02359","02252","09606","01456","03759","09939","09995","BK1147","BK1574","01530"],"gpt_icon":0},{"id":"2613405217","title":"45天狂攬490億美元，2026中國創新藥BD加速升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2613405217","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613405217?lang=zh_tw&edition=fundamental","pubTime":"2026-02-21 10:31","pubTimestamp":1771641097,"startTime":"0","endTime":"0","summary":"2026年开年，中国创新药对外BD交易势头不减，再攀新高。这意味着，开年45天，中国创新药对外BD交易首付款规模已超过2025年任一季度，总金额更已超过2025年全年水平的1/3。而对于这8个极早期项目，阿斯利康开出了12亿美元首付款、185亿美元总金额的高价，也让这笔交易成为中国创新药BD历史上总金额最大的交易。勃林格殷格翰则以4,200万欧元、10.16亿欧元里程碑付款获得了先声药业TL1A/IL-23p19双抗SIM0709的大中华区外全球权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221104715a4b8203c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221104715a4b8203c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1951186391.HKD","06978","LU1226287792.SGD","02096","LU0314109678.HKD","LU2039709279.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0067412154.USD","IE00B5MMRT66.SGD","BK1574","LU0072913022.USD","LU1993786604.SGD","LU1807302812.USD","IE0008369823.USD","BK1515","LU1226287529.USD","LU1226288170.HKD","SG9999004220.SGD","LU1152091168.USD","LU0315179316.USD","06938","IE0008368742.USD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1161","IE00B031HY20.USD","01093","LU0140636845.USD","LU0880133367.SGD","LU0501845795.SGD","LU1813983027.USD","LU1226288253.USD","01801","BK1191","HK0000165453.HKD","IE00B543WZ88.USD","LU1226287875.USD","BK1521","LU1960683339.HKD","LU1328277881.USD","LU1008478684.HKD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2612230236","title":"中金：首予瑞博生物-B(06938)「跑贏行業」評級 目標價100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230236","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612230236?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 09:58","pubTimestamp":1771552683,"startTime":"0","endTime":"0","summary":"截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06938"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}]}}